9-27-04

IFW

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR ENCLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

PATENTS PO BOX 1450 ALEXANDRIA, VA 22313-1450

Elaine C. Stracker

PATENT

Attorney's Docket No.: 00043.05CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Rabinowitz et al.

Serial No.:

10/766,279

Filed:

1/27/2004

Title

DELIVERY OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS

THROUGH AN INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

П	ata.
1)	are:

SEP. 24 2004

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999

PTO/SB/21 (08-03)

Under the Paperwork Reduction Act of 1995,	no persons are required	Patent and Tradem	ved for use through 07/31/2006. OMB 0651-0031 ark Office: U.S. DEPARTMENT OF COMMERCE on unless it displays a valid OMB control number.
		Application Number	10/766,279
TRANSMIT	ΓAL	Filing Date	1/27/2004
FORM		First Named Inventor	Joshua D. Rabinowitz
(to be used for all correspondence at	ter initial filing)	Art Unit	Not yet known
		Examiner Name	To be assigned
Total Number of Pages in This Submissi	on	Attorney Docket Number	00043.05CON
	ENCLOS	URES (check all that apply)	
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request	Petition Petition t Provisior Power of Change Terminal	g-related Papers o Convert a nal Application f Attorney, Revocation of Correspondence	After Allowance communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below):
Express Abandonment Request Information Disclosure Statement		for Refund nber of CD(s)	
Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks Info. Discl. State Form 1449 (3 co Copy of Arefe Return Fostcare	ppies, 8 pages each) erences /69	
SIGNAT	URE OF APPLICA	NT, ATTORNEY, OR AGEN	Γ
or Individual name Signature		Sircle, Palo Alto, CA 94303 ephone (650)-687-3905	Customer Number 37485
	-		
I hereby certify that this correspondence is	eing facsimile transn		
Typed or printed name Elaine C. Str	acker	1	

Signature Date SFP 2 4 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SEP 2 4 2004
Rorm PTO-1449

ÁTION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00043.05CON	Application Number: 10/766,279

Applicant: Joshua D. RABINOWITZ et al.

Filing Date: 1/27/2004 Group Art Unit: Not Yet Known

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/02/1971	3,560,607	Hartley et al.			
	2.	05/27/1980	Re. 30,285	Babington			
	3.	01/23/1990	4,895,719	Radhakrishnun et al.			
	4.	09/17/1991	5,049,389	Radhakrishnun			
	5.	02/14/1995	5,388,574	Ingebrethsen			
	6.	08/13/1996	5,544,646	Lloyd et al.			
	7.	12/09/1997	5,694,919	Rubsamen et al.			
	8.	03/10/1998	5,724,957	Rubsamen et al.			
	9.	04/07/1998	5,735,263	Rubsamen et al.			
	10.	04/14/1998	5,738,865	Baichwal et al.			
	11.	06/02/1998	5,758,637	Ivri et al.			
	12.	06/29/1999	5,915,378	Lloyd et al.			
	13.	08/10/1999	5,934,272	Lloyd et al.			
	14.	09/28/1999	5,957,124	Lloyd et al.			
	15.	10/05/1999	5,960,792	Lloyd et al.			
	16.	11/30/1999	5,993,805	Sutton et al.			
	17.	03/28/2000	6,041,777	Faithfull et al.			
	18.	04/18/2000	6,051,566	Bianco			
	19.	08/01/2000	6,095,134	Sievers et al.			
	20.	08/01/2000	6,095,153	Kessler et al.			
	21.	08/15/2000	6,102,036	Slutsky et al.			
	22.	06/05/2001	6,241,969	Saidi et al.			
	23.	07/03/2001	6,255,334	Sands			
	24.	10/09/2001	6,299,900	Reed et al.			
	25.	10/23/2001	6,306,431	Zhang et al.			
	26.	01/14/2003	6,506,762	Horvath et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sheet 2 of 8

Form PTO-14	INFORMATION DISCLOSURE CITATION IN AN APPLICATION Applicant: Joshua D. RABINOWITZ e		Docket Number: 00043. 05CON Application Number: 10/766,279			
). RABINOWITZ et al.	al.		
			Filing Date: 1/27/2004	Group Art Unit:	Not Yet Know	
27.	02/04/2003	6,514,482	Bartus et al.			
28.	07/15/2003	6,591,839	Meyer et al.			
29.	09/06/2001	US 2001/0020147	Staniforth et al.			
	 	US 2002/0037828	Wilson et al.			
30.	03/28/2002	US 2002/0037828 US 2002/0058009	Bartus et al.			
31.	05/16/2002					
32.	05/23/2002	US 2002/0061281	Osbakken et al.			
33.	07/04/2002	US 2002/0086852	Cantor Cantor of all	_		
34.	08/22/2002	US 2002/0112723	Schuster et al.			
35.	11/28/2002	US 2002/0176841	Barker et al. Prior et al.	·		
36.	01/02/2003	US 2003/0004142				
37.	02/13/2003	US 2003/0032638	Kim et al.			
RELA	TED ALEXZA	MOLECULAR DELI	VERY CORPORATION	PATENT DOCUM	MENTS	
38.	08/04/2003	10/633,876	Hale et al.		······································	
39.	08/04/2003	10/633,877	Hale et al.	·		
40.	12/30/2003	10/749,537	Rabinowitz et al.			
41.	12/30/2003	10/749,539 /	Rabinowitz et al.			
42.	01/27/2004	10/766,149	Rabinowitz et al.			
43.	01/27/2004	10/766,566	Rabinowitz et al.			
44.	01/27/2004	10/766,574	Rabinowitz et al.			
45.	01/27/2004	10/766,634	Rabinowitz et al.	8		
46.	01/27/2004	10/766,647	Rabinowitz et al.			
47.	01/28/2004	10/767,115 ,	Rabinowitz et al.			
48.	01/29/2004	10/768,205	Rabinowitz et al.			
49.	01/29/2004	10/768,220	Rabinowitz et al.			
50.	01/29/2004	10/768,281	Rabinowitz et al.			
51.	01/29/2004	10/768,293 ,	Rabinowitz et al.			
52.	01/30/2004	10/769,046 ·	Rabinowitz et al.	·		
53.	01/30/2004	10/769,051	Rabinowitz et al.			
54.	01/29/2004	10/769,157	Rabinowitz et al.			
	01/29/2004	10/769,197	Rabinowitz et al.		•	
55.						

PTO/SB/ 08 (2-92)

Sheet 3 of 8

Application Number: 10/766,279 Docket Number: 00043.05CON Form PTO-1449 Joshua D. RABINOWITZ et al. INFORMATION DISCLOSURE CITATION Applicant: IN AN APPLICATION Group Art Unit: Not Yet Known 1/27/2004 · (Use several sheets if necessary) Filing Date: Rabinowitz et al. 02/09/2004 10/775,583 56. Rabinowitz et al. 57. 02/09/2004 10/775,586 10/791,915 Hale et al. 03/03/2004 58. Rabinowitz et al. 59. 03/03/2004 10/792,001 60. 03/03/2004 10/792,012 Hale et al. 03/03/2004 Rabinowitz et al. 10/792,013 61. 10/792,096 Hale et al. 62. 03/03/2004 10/792,239 Hale et al. 63. 03/03/2004 03/31/2004 10/813,721 Rabinowitz et al. 64. Rabinowitz et al. 10/813,722 65. 03/31/2004 03/31/2004 Rabinowitz et al. 10/814,690 / 66. 10/814,998 Rabinowitz et al. 03/31/2004 67. 10/815,527 Rabinowitz et al. 68. 04/01/2004 Rabinowitz et al. 10/816,407 69. 04/01/2004 Rabinowitz et al. 04/01/2004 10/816,492 70. Rabinowitz et al. 71. 04/01/2004 10/816,567 Hale et al. 08/04/2004 10/912,462 72. 01/23/2003 US 2003/0015196 Hodges et al. 73. Wensley et al. US 2003/0062042 74. 04/03/2003 Hale et al. 75. 11/13/2003 US 2003/0209240 Rabinowitz et al. 76. 01/02/2003 US 2003/0000518 Rabinowitz et al. US 2003/0005924 77. 01/09/2003 US 2003/0005925 Hale et al. 78. 01/09/2003 US 2003/0007933 Rabinowitz et al. 79. 01/09/2003 US 2003/0007934 Rabinowitz et al. 01/09/2003 80. US 2003/0012737 Rabinowitz et al. 81. 01/16/2003 01/16/2003 US 2003/0012738 Rabinowitz et al. 82. US 2003/0012740 Rabinowitz et al. 83. 1/16/2003 01/23/2003 US 2003/0015189 Rabinowitz et al. 84. Rabinowitz et al. 01/23/2003 US 2003/0015190 85.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

orm P	TO-144	19		Docket Number: 00	043. 05CON	Application Numb	er: 10/766,279
INF		TION DISCLO	OSURE CITATION CATION	Applicant:	Joshua D. R.	ABINOWITZ et al.	
		(Use several sheets ij		Filing Date:	1/27/2004	Group Art Unit:	Not Yet Known
•							
	86.	01/23/2003	US 2003/0017114	Rabinowitz et al.			
7	87.	01/23/2003	US 2003/0017115	Rabinowitz et al.			
	88.	01/23/2003	US 2003/0017116	Rabinowitz et al.			
 ა	89.	01/23/2003	US 2003/0017117	Rabinowitz et al.			
<u>,</u>	90.	01/23/2003	US 2003/0017118	Rabinowitz et al.			
	91.	01/23/2003	US 2003/0017119	Rabinowitz et al.			
	92.	01/23/2003	US 2003/0017120	Rabinowitz et al.			·
<u> </u>	93.	1/30/2003	US 2003/0021753	Rabinowitz et al.			
	94.	01/30/2003	US 2003/0021754	Rabinowitz et al.			
	95.	01/30/2003	US 2003/0021755	Hale et al.			
<u></u> ن	96.	02/20/2003	US 2003/0035776	Hodges et al.			
٥	97.	05/15/2003	US 2003/0091511	Rabinowitz et al.			
J	98.	05/27/2004	US 2004/010148	Hale et al.			·
ر,	99.	07/31/2003	US 2003/0138382	Rabinowitz			
. J	100.	11/06/2003	US 2003/0206869	Rabinowitz et al.			
.)	101.	01/15/2004	US 2004/0009128	Rabinowitz et al.			· · · · · · · · · · · · · · · · · · ·
J	102.	05/20/2004	US 2004/0096402	Hodges et al.			
,	103.	05/27/2004	US 2004/0099269	Hale et al.			
ز	104.	06/03/2004	US 2004/0105818	Hale et al.			
,	105.	06/03/2004	US 2004/0105819	Hale et al.			
J	106.	07/01/2004	US 2004/0126326	Rabinowitz et al.			
v	107.	07/01/2004	US 2004/0126327	Rabinowitz et al.			
j	108.	07/01/2004	US 2004/0126328	Rabinowitz et al.			
~)	109.	07/01/2004	US 2004/0126329	Rabinowitz et al.			
	110.	07/01/2004	US 2004/0127481 /	Rabinowitz et al.			
0	111.	07/01/2004	US 2004/0127490	Rabinowitz et al.			
	112.	08/12/2004	US 2004/0156788 ~	Rabinowitz et al.			
Ŋ	113.	08/12/2004	US 2004/0156789	Rabinowitz et al.			
(c)	114.	8/12/2004	US 2004/0156790	Rabinowitz et al.			
Ō	115.	08/12/2004	US 2004/0156791	Rabinowitz et al.			
EXAN	INER:			DATE CO	NSIDERED:		
			sidered, whether or not the cita nclude a copy of this form with			v a line through the cit	ation if not in
TO/SB/ 0	8 (2-92)	- ,		Patent and Tr	ademark Office	; U.S. DEPARTMEN	T OF COMMERCE

Sheet 5 of 8

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:	00043. 05CON	Application Number	er: 10/766,279
Applicant: Joshua D. RABI		BINOWITZ et al.	
Filing Date:	1/27/2004	Group Art Unit:	Not Yet Known

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
······································	116.	03/14/1990	EP 0 358 114 -	Europe			
	117.	07/20/1994	EP 0 606 486	Europe			
	118.	07/03/2001	EP 1 080 720	Europe			
	119.	06/13/1991	WO 91/07947 '	WIPO			
	120.	04/16/1992	WO 92/05781 /	WIPO			
	121.	04/11/1996 .	WO 96/09846 /	WIPO			
	122.	05/09/1996	WO 96/13161 /	WIPO			
	123.	05/09/1996	WO 96/13290 /	WIPO			
	124.	05/09/1996	WO 96/13291 /	WIPO			
	125.	05/09/1996	WO 96/13292 🗸	WIPO			
	126.	10/03/1996	WO 96/30068 '	WIPO .		·	
	127.	08/07/1997	WO 97/27804 4	WIPO			
	128.	05/28/1998	WO 98/22170 /	WIPO			
	129.	07/23/1998	WO 98/31346 /	WIPO			
	130.	08/27/1998	WO 98/36651 '	WIPO			1)1
	131.	04/08/1999	WO 99/16419 /	WIPO			
	132.	12/16/1999	WO 99/64094 /	WIPO			
	133.	01/06/2000	WO 00/00176 /	WIPO			
,	134.	01/06/2000	WO 00/00215 /	WIPO			
	135.	05/18/2000	WO 00/27363 /	WIPO			
	136.	05/25/2000	WO 00/29053 ′	WIPO		10.	
	137.	9/17/2000	WO 00/47203 /	WIPO	- 00		·
	138.	11/02/2000	WO 00/64940 /	WIPO			
	139.	11/09/2000	WO 00/66084 /	WIPO		_0_0	
	140.	11/09/2000	WO 00/66206 /	WIPO			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

rm PTO-1449	Docket Number: 00043.05CON	Application Number: 10/766,279		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Joshua D. RABINOWITZ et al.			
(Use several sheets if necessary)	Filing Date: 1/27/2004	Group Art Unit: Not Yet Know		
141. 12/21/2000 WO 00/76673 -	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
142. 01/25/2001 WO 01/05459 /	WIPO			
143. 03/01/2001 WO 01/13957	WIPO			
144. 03/28/2002 WO 02/24158 /	WIPO			
		•		
	•			
•				
	•	•		
·	•	,		
		•		
		•		
	•			
		•		
Y.				
	•			
EXAMINER:	DATE CONSIDERED:			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	145.	Bennett, R.L. et al. (1981). "Patient-Controlled Analgesia: A New Concept of Postoperative Pain Relief," <i>Annual Surg.</i> 195(6):700-705.
	146. /	Carroll, M.E. et al. (1990), "Cocaine-base smoking in rhesus monkeys: reinforcing and physiological effects," <i>Psychopharmacology</i> (Berl). 102:443-450.
	147.	Clark, A. and Byron, P. (1986). "Dependence of Pulmonary Absorption Kinetics on Aerosol Particle Size," Z. Erkrank. 166:13-24.
	148.	Darquenne, C. et al. (1997). "Aerosol Dispersion in Human Lung: Comparison Between Numerical Simulations and Experiments for Bolus Tests," <i>American Physiological Society</i> . 966-974.
	149. /	Davies, C.N. et al. (May 1972). "Breathing of Half-Micron Aerosols," <i>Journal of Applied Physiology</i> . 32(5):591-600.
	150.	Dershwitz, M., M.D., et al. (September 2000). "Pharmacokinetics and Pharmacodynamics of Inhaled versus Intravenous Morphine in Healthy Volunteers," <i>Anesthesiology</i> . 93(3): 619-628.
	151.	Finlay, W.H. (2001). "The Mechanics of Inhaled Pharmaceutical Aerosols", Academic Press: San Diego Formula 2.39. pp.3-14 (Table of Contents). pp. v-viii.
	152. /	Gonda,I. (1991). "Particle Deposition in the Human Respiratory Tract," Chapter 176, <u>The Lung: Scientific Foundations</u> . Crystal R.G. and West, J.B. (eds.), Raven Publishers, New York. pp. 2289-2294.
	153.	Hatsukami D, et al. (May 1990) "A method for delivery of precise doses of smoked cocaine-base to humans." <i>Pharmacology Biochemistry & Behavior</i> . 36(1):1-7.
	154. /	Heyder, J. et al. (1986). "Deposition of Particles in the Human Respiratory Tract in the Size Range 0.005-15 µm," J. Aerosol Sci. 17(5):811-822.
	155.	Huizer, H., "Analytical studies on illicit heron. V. Efficacy of volatilization during heroin smoking." <i>Pharmaceutisch Weekblad Scientific Edition</i> (1987). 9(4):203-211.
	156.	Hurt, R.D., MD and Robertson, C.R., PhD, (October 1998). "Prying Open the Door to the Tobacco Industry's Secrets About Nicotine: The Minnesota Tobacco Trial," <i>JAMA</i> 280(13):1173-1181.
	157.	Lichtman, A.H. et al. (1996). "Inhalation Exposure to Volatilized Opioids Produces Antinociception in Mice," Journal of Pharmacology and Experimental Therapeutics. 279(1):69-76.
	158. _j	Martin, B.R. and Lue, L.P. (May/June 1989). "Pyrolysis and Volatilization of Cocaine," <i>Journal of Analytical Toxicology</i> 13:158-162.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92)

Sheet 8 of 8

Form PTO-1449		Docket Number: 00043. 05CON Application Number: 10/766,279			
	ON DISCLOSURE CITATION AN APPLICATION	Applicant:	Joshua D. RAF	BINOWITZ et al.	
	se several sheets if necessary)	Filing Date:	1/27/2004	Group Art Unit:	Not Yet Known
159.	Mattox, A.J. and Carroll, M.E., (1996) Psychopharmacology, 125:195-201.). "Smoked he	roin self-administ	ration in rhesus r	nonkeys,"
160.	Meng, Y. et al. "Inhalation Studies Wi 173:201-224.				<u></u>
161.	Meng, Y., et al. (1999). "Pharmacolog inhalation exposure," Drug and Alcohol	ol Dependenc	e. 53:111-120.		
162.	Office Action mailed 8/13/2003 for US BENZODIAZEPINES THROUGH	I AN INHAL	LATION ROUT	Е"	
163.	Pankow, J.F. et al. (1997). "Conversion Free-Base Form Through the Action of	f Gaseous An	monia," Envron.	Sci. Technol. 31:	2428-2433.
164.	Pankow, J. (March 2000). ACS Confe pp. 1-8.	rence-San Fra	ncisco-3/26/00. C	Chemistry of Toba	acco Smoke.
165.	Seeman, J. et al. (1999). "The Form of Nicotine Acid Salts to Nicotine in the	f Nicotine in T Gas Phase, "J	Tobacco. Thermal I. Agric. Food Ch	Transfer of Nico em. 47(12):5133-	tine and 5145.
166.	Sekine, H. and Nakahara, Y. (1987). "Inhalation Efficiency and Pyrolysis Pr 32(5):1271-1280.	Abuse of Smo oducts of Met	oking Methamphe hamphetamine,".	tamine Mixed wi Journal of Foren	th Tobacco: 1. sic Science
167.	Vapotronics, Inc. (1998) located at htt June 5, 2000).	p://www.vapc	otronics.com.au/ba	anner.htm., 11 pa	ges, (visited on
168.	Ward, M.E. MD, et al. (December199 Administration from a Novel Aerosol 62(6):596-609.	7). "Morphine Delivery Syst	e Pharmacokinetic em," <i>Clinical Pha</i>	es after Pulmonar armacology & Th	y erapeutics
169.	Wood, R.W. et al. (1996). "Generation Pyrolyzate, Methylecgonidine, and De Biochemistry & Behavior. 55(2):237-2	emonstration of			
			. •		
,					
			·		•
EXAMINER:		DATE	CONSIDERED:		
	ial if citation considered, whether or not the citation considered. Include a copy of this form with			line through the cita	tion if not in